1 Day Virtual Good Clinical Practice (ICH GCP) Course: Core Requirements, Expectations and Challenges - August 25, 2022 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Good Clinical Practice (ICH GCP) Course : Core Requirements, Expectations and Challenges" training has been added to ResearchAndMarkets.com's offering.
This webinar is intended to help you adequately implement Good Clinical Practices (GCP) including documentation requirements during clinical trials for both drugs and medical devices.
GCP consists of basic and refresher courses that provide essential good clinical practice training for research teams involved in clinical trials of drugs, biologics, and devices, as well as those involved in behavioral intervention and social science research studies.
Good Clinical Practice (GCP) is the international ethical, scientific and practical standard to which all clinical research is conducted. It is important that everyone involved in research is trained or appropriately experienced to perform the specific tasks they are being asked to undertake.
We recommend that team members leading and delivering research complete, as a minimum, the Introduction to Good Clinical Practice (GCP) course (online or face-to-face).This should be followed by additional specialist courses where appropriate (e.g. Informed Consent) andregular GCP Refresher training.
In this 180 minutes Instructor led Live webinar, you will have unparalleled opportunities to bring great value and benefits to your organization and to greatly improve your GCPs with increased awareness of the needs - sustainable compliance
Who Should Attend:
- Clinical Affairs
- Regulatory Affairs
- Quality Assurance
- Research & Development
- Senior Management
- Anyone Interested in the Topic
Key Topics Covered:
Session 1: Good Clinical Practice (GCP) Refresher Training
- 21 CFR 11, Electronic Records/Electronic Signatures
- 21 CFR Part 50: Protection of Human Subjects - Informed Consent (and IRB's)
- 21 CFR Part 54: Financial Disclosure by Clinical Investigators
- 21 CFR Part 56: Reporting and Recordkeeping requirements
- 21 CFR Part 312: Investigational New Drug Application
- 21 CFR Part 314: Application for Approval to Market a New Drug
Break/Q & A
Session 2: ICH E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1), Guidance for Industry - Brief Overview
- Investigator's Responsibilities
- Sponsor's Responsibilities
- Monitor's Responsibilities
- Essential Documents
Conclusion: Summarization; Q&A
John E. Lincoln
J. E. Lincoln and Associates LLC
John E. Lincoln is principal of J. E. Lincoln and Associates LLC, a consulting company, with over 33 years' experience in U.S. FDA-regulated industries and 20 years as a full-time consultant. He has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan.
He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process/ product/ equipment including QMS and so+E6ftware validations, ISO 14971 product risk management files / reports, design control / design history files, and technical files.
He's held positions in manufacturing engineering, QA, QAE, regulatory affairs, to the level of director and VP (R&D). In addition, Mr. Lincoln has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CGMP subjects. He is a graduate of UCLA.
For more information about this training visit https://www.researchandmarkets.com/r/ddob6
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900